I tend to focus on biotechnology and drug discovery, but I have written widely about science, technology, and the environment. My credits include Science, Nature, Scientific American, Inc. Magazine, WebMD, Popular Science online, Technology Review, and newsletters of the Harvard Business School. I've written about marketing, anthropology, ecology, geology, physics, and corporate management. For a more general description of my writing career, see my highlights page.

Much of my focus is now on how various economic, regulatory, and political forces influence the biotechnology industry. For example, in the June 2003 issue of Nature Biotechnology, I wrote an article about FDA's attempts to cope with pharmacogenomics data (so-called personal medicine, in which a patient's genetic makeup could be used to predict outcomes) and the potentially negative effect it could have on drug development programs in industry. For the June 2005 issue of Technology Review, I profiled GlaxoSmithKline's unique strategy of introducing a novel vaccine first into third world countries, foregoing the traditional route of introducing it first in the US or Europe.

I also try my hand at science fiction from time to time. In 2000, I sold a short story to Nature, entitled 'The Flaw is Human: The End of the Human Genome Reclamation Project.' A 2nd story, tentatively titled 'The Bell Curve Drug,' will be published in Nature later this year.

I occasionally post musings on my LiveJournal page.

Contact me